Obesity and Diabetes
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 113715 in Patients With Type 2 Diabetes
Published in Obesity and Diabetes Week, November 2nd, 2009
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control. In addition to lowering blood glucose, ISIS 113715 caused statistically significant and clinically meaningful reductions in LDL cholesterol. Consistent with the preclinical data with ISIS 113715, a tendency toward weight loss was observed even in this short-term study...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- BioMed Central
Mangosteen juice could protect health in the obese - Johns Hopkins Medical Institutions
Physicians have less respect for obese patients, study suggests - University of Adelaide
Strong link between obesity and depression - University of Florida
Phytochemicals in plant-based foods could help battle obesity, disease - Cardiovascular Disease
Studies from Columbus Children's Hospital describe new findings in cardiovascular disease - Diabetes
Study results from H.P.S. Sachdev and colleagues update understanding of diabetes - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
